Be part of the Pharmaceutical Industry’s Global Think Tank on SPCs and Patent Extensions

This year’s C5’s Pharma Patent Term Extensions Forum arrives at a critical time for the pharmaceutical industry. Overarching developments from the Teva U.K. decision (C-121/17) to the SPC Manufacturing Waiver and the most recent CJEU Abraxis decision are expected to have a significant impact on the future of the pharmaceutical and biotech industries.

Be part of an exclusive gathering of leading in-house IP counsel, patent attorneys, representatives from multi-jurisdiction patent offices and policy authorities from around the globe who will share their insights on the complexities of SPCs and other types of patent extensions. They will provide you with comprehensive knowledge to ensure that you are leading the way in patent protection for your company and clients.

2019 CO-CHAIRS:
 
Dr. Christian Drescher
Head of Patent Affairs
Midas Pharma
Robin Ellis
Head Patents – IP Product Strategy
Sandoz
Regulatory Speakers:
 
Alfonso Callez-Sanchez
Policy Officer
European Commission
Dr. Oliver Werner
Head of SPC Working Group
German Patent & Trade Mark Office
Pierre Treichel
International Legal Affairs
European Patent Office
Dr. Martijn de Lange
Patent Examiner
Netherlands Patent Office
Inês Cristóvão da Silva
Head of Patent and Utility Model Department
Instituto Nacional da Propriedade Industrial (INPI)
Indira Lemont-Spire
Legal Expert – Europe and International
INPI (France Patent Office)
REGISTER NOW

2019 Topics will include:

  • Supplementary Protection Certificate Regulation Article 3(a) and (d): Exploring questions of derivatives and the scope of SPC legitimacy.
  • The Practical aftermath of the Teva U.K. decision (C-121/17)
  • European Commission amendments to the SPC regulation for medicinal products (EC) 469/2009 of 6 May 2009)
  • The Imminent arrival of SPC / PTE in China
  • SPC eligibility for new formulations of old drugs in Europe in light of the CJEU decision on Art. 3(d) in Abraxis
  • Post Brexit Effect on the legalities and enforcement of SPC
  • Developments in the U.S affecting patent term extension (PTE) and patent term adjustment (PTA)

THE CONFERENCE WILL PROVIDE INSIGHTS ON ALL THIS AND OTHER KEY CHALLENGES!

THIS IS AN ESSENTIAL EVENT FOR

Pharmaceutical and Biotech Companies:
  • Global Patent Attorney
  • Patent Examiner
  • Head of Patent
  • Chief Patent Counsel
  • VP Patent Law
  • Patent & Legal Managers
  • Legal Director
  • Senior Counsel, Global Patents
  • Head of Intellectual Property Rights
  • Head of Patent Strategies & Litigation
  • Head of Legal
Private Practice Lawyers and Patent Attorneys specialising in:
  • IP and Patent Extensions
See what’s new for 2019 – Agenda and speakers list is now available.
VIEW COMPLETE AGENDA

OUR PRIOR DELEGATES SAY IT BEST:

“I was pleasantly surprised by the content. There was less repetition than previous events; the general quality and variety of speakers was good and I certainly learned something.”   Robin Ellis Head of IP, Sandoz
“Good conference with international coverage from Europe as well as the rest of the world. Good and interesting speakers.”   Dorte Petersen, Senior Examiner, The Danish Patent and Trademark Office
“A great and info-rich conference.”   Ronnie Benshafrut Patent Attorney, Reinhold Cohn and Partners
 
REGISTER NOW

Hotel